08.19.15
Siegfried
1H Revenues: CHF 200.7 million (+22%)
1H Earnings: CHF 20.1 million (+7%)
Comments: Sales of active pharmaceutical ingredients grew by 3%, driven by API synthesis, which grew 28% in the first half. Finished dosage forms grew 81%, mainly from the acquisition of Hameln Pharma at the end of 2014. The new production facility in Nantong was inaugurated in the first half and the company completed the acquisition of several segments of BASF’s pharmaceutical supply business.
1H Revenues: CHF 200.7 million (+22%)
1H Earnings: CHF 20.1 million (+7%)
Comments: Sales of active pharmaceutical ingredients grew by 3%, driven by API synthesis, which grew 28% in the first half. Finished dosage forms grew 81%, mainly from the acquisition of Hameln Pharma at the end of 2014. The new production facility in Nantong was inaugurated in the first half and the company completed the acquisition of several segments of BASF’s pharmaceutical supply business.